Insiders At Krystal Biotech Sold US$16m In Stock, Alluding To Potential Weakness
Insiders At Krystal Biotech Sold US$16m In Stock, Alluding To Potential Weakness
Over the past year, many Krystal Biotech, Inc. (NASDAQ:KRYS) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying versus if they selling is usually more beneficial, as the latter can be open to many interpretations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
在過去的一年裡,許多人克裡斯特爾生物技術公司。納斯達克(Sequoia Capital:Krys)內部人士出售了該公司的大量股份,這可能激起了投資者的興趣。在評估內幕交易時,瞭解內部人士是在買入還是在賣出通常更有利,因為後者可能會有多種解讀。然而,如果有幾個內部人士在特定時間段內出售股票,股東們應該更深入地研究一下。
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
儘管我們不認為股東應該簡單地跟蹤內幕交易,但我們確實認為,密切關注內部人士的所作所為是完全合乎邏輯的。
Check out our latest analysis for Krystal Biotech
查看我們對Krystore Biotech的最新分析
The Last 12 Months Of Insider Transactions At Krystal Biotech
克裡斯特爾生物技術公司過去12個月的內幕交易
The Lead Independent Director, Daniel Janney, made the biggest insider sale in the last 12 months. That single transaction was for US$6.4m worth of shares at a price of US$129 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$116). So it is hard to draw any strong conclusion from it.
獨立董事首席執行官Daniel·詹尼在過去12個月裡進行了最大規模的內幕交易。這一筆交易是以每股129美元的價格收購了價值640萬美元的股票。雖然我們通常不喜歡看到內幕出售,但如果以更低的價格出售,人們更擔心的是。一線希望是,這次拋售發生在最新價格(116美元)之上。因此,很難從中得出任何強有力的結論。
In the last year Krystal Biotech insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
去年,克裡斯特爾生物科技公司的內部人士沒有購買任何公司股票。下面的圖表顯示了過去一年的內幕交易(按公司和個人)。通過點擊下面的圖表,你可以看到每一筆內幕交易的準確細節!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231003/0-aa9d5fdd7fbe11ad9ec10ae45c42ddd4-0-acaa3e10d51878736bb08239652a3238.png/big)
I will like Krystal Biotech better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我看到一些大的內部收購,我會更喜歡克裡斯特爾生物科技公司。在我們等待的時候,看看這個免費最近有大量內幕收購的成長型公司名單.
Insider Ownership Of Krystal Biotech
克裡斯特爾生物技術公司的內部人所有權
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Krystal Biotech insiders own 13% of the company, currently worth about US$412m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
對於一個普通股股東來說,公司內部人士持有多少股份值得一查。通常,內部人持股越高,內部人就越有可能受到激勵,建立長期的公司。Krystore Biotech內部人士擁有該公司13%的股份,根據最近的股價,目前價值約為4.12億美元。這種由內部人士持有的重大所有權通常確實增加了公司以所有股東的利益運營的機會。
So What Does This Data Suggest About Krystal Biotech Insiders?
那麼,這些數據對克裡斯特爾生物技術公司的內部人士有什麼啟示呢?
The fact that there have been no Krystal Biotech insider transactions recently certainly doesn't bother us. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Krystal Biotech insider transactions don't fill us with confidence. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For instance, we've identified 2 warning signs for Krystal Biotech (1 is significant) you should be aware of.
最近沒有發生克裡斯特爾生物技術公司的內幕交易,這一事實當然不會讓我們感到困擾。令人振奮的是,內部人士擁有大量股票,但我們希望看到更多的內部人士購買,因為去年Krystore Biotech的內部交易並沒有讓我們充滿信心。因此,這些內幕交易可以幫助我們建立一個關於股票的論文,但瞭解這家公司面臨的風險也是值得的。例如,我們已經確定克裡斯特爾生物技術公司的兩個警告信號(1是重要的)您應該知道。
Of course Krystal Biotech may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然了Krystore Biotech可能不是最值得購買的股票那就是。所以你可能想看看這個免費匯集了高質量的公司.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前只處理公開市場交易和私下處置直接權益,而不處理衍生工具交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.